Bristol-Myers Squibb Company (BMY) 2024 10-K Earnings Analysis
Bristol-Myers Squibb Company2024 Earnings Analysis
72/100
Bristol Myers Squibb's FY2024 is a patent-transition story disguised as a GAAP loss: $48.3B revenue, a reported -$8.95B net loss after Karuna and RayzeBio acquisition charges, but $13.9B of free cash flow from the underlying portfolio. Eliquis and Opdivo still fund the enterprise, while Camzyos, Cobenfy, Reblozyl and other newer assets are being asked to bridge the Revlimid decline. The real analytical task is to separate temporary purchase-accounting noise from the harder question of whether the replacement portfolio can scale quickly enough.
Filing analysis
Bristol-Myers Squibb Company 2024 10-K Analysis
This page reads Bristol-Myers Squibb Company's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 72/100, or grade C.
BMY Earnings Quality
The earnings-quality module scores 72/100, with Gross Margin: 71.1%, Reported Net Loss: -$8.95B. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
BMY Economic Moat Analysis
The moat-strength module scores 76/100, with Eliquis Franchise: Anticoagulant leadership, Oncology IO Portfolio: Opdivo, Opdualag. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
BMY Free Cash Flow vs Net Income
CF/Net Income (skewed): N/M is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
BMY Key Risks from the Annual Report
The risk module scores 62/100, with Revlimid LOE: Staggered generic entry, IRA Drug Pricing: Eliquis selected. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is BMY a High Quality Earnings Stock?
Based on this 2024 filing, BMY needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 72/100. This is a research screen, not investment advice.
Read the report first
Understand Bristol-Myers Squibb Company first, then decide if it belongs on your watchlist
The BMY score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep BMY with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the BMY report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 71.1% is consistent with a branded-pharma business. The margin is insulated from the IPRD write-off that falls below the gross-profit line.
Per the FY2024 10-K income statement, net loss of $8.95B reflects approximately $12B+ in acquired-IPRD (in-process research and development) charges — non-cash purchase-accounting items disclosed in the acquisition footnote for the Karuna Therapeutics and RayzeBio transactions closed in 2024.
Per the FY2024 cash flow statement, OCF of $15.2B contrasts with the -$8.95B reported NI. The apparent negative CF/NI ratio is a consequence of the IPRD write-off not affecting cash; OCF is the cleaner read of underlying earning-power for the period.
Per the FY2024 MD&A, revenue composition is shifting from Revlimid (post-loss-of-exclusivity and going through staggered generic entry per the Celgene-heritage settlement) toward the growth portfolio — Eliquis (anticoagulant), Opdivo (IO), Opdualag, Reblozyl, Camzyos, Breyanzi, Cobenfy (post-Karuna), plus the pipeline.
Earnings quality scores 72/100. BMS's FY2024 GAAP loss does not describe the operating business very well, because acquired-IPRD charges from the 2024 M&A wave overwhelmed the income statement. The cleaner read is still the cash statement: this is a large biopharma franchise generating substantial cash while simultaneously digesting a patent cliff and trying to accelerate the next product set.
Moat Strength
Per the FY2024 product-revenue disclosures, Eliquis (apixaban, co-developed with Pfizer per the partnership agreement) is the largest revenue product line. The anticoagulant category has a disclosed Medicare Drug Price Negotiation exposure under the IRA framework — Eliquis is on the first list of selected drugs per HHS public announcements.
Per the FY2024 10-K product disclosures, BMS's oncology portfolio includes Opdivo (PD-1 immuno-oncology), Opdualag (PD-1/LAG-3 combo), Breyanzi (CAR-T), Abecma (CAR-T with partner 2seventy bio per the partnership), Reblozyl (anemia). The IO portfolio has broad indication coverage per the publicly-approved label extensions.
Per the FY2024 MD&A and product-launch press releases, the growth portfolio includes Camzyos (HCM cardiomyopathy), Cobenfy (schizophrenia via the Karuna acquisition per the closing press release), Sotyktu (psoriasis), Reblozyl, and Opdualag. Management frames these as the post-Revlimid revenue-bridge trajectory.
Goodwill of $22B on $93B assets equals 23.5% per the FY2024 balance sheet — reflecting principally the 2019 Celgene acquisition (~$74B per the closing press release) plus the 2024 Karuna and RayzeBio acquisitions. Note that goodwill is separate from the IPRD charges that hit the income statement.
Moat strength scores 76/100. BMS's moat today is less about one unbeatable franchise and more about whether a broad oncology-and-immunology portfolio can successfully hand the baton from older blockbusters to newer growth assets. Eliquis and Opdivo still matter enormously, but the durability case now depends on portfolio replacement discipline, not on endless life-cycle extensions of one or two legacy products.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $13.9B (OCF $15.2B minus capex $1.25B) supports the dividend (raised multiple times per the dividend-history disclosure) plus debt reduction and pipeline investment.
Per Bristol Myers Squibb's 2024 Karuna Therapeutics closing press release (approximately $14B transaction) and RayzeBio closing press release, the two transactions added Cobenfy (muscarinic-receptor-agonist for schizophrenia) and radiopharmaceutical-platform assets. The combined $12B+ IPRD write-off reflects the early-stage value allocation.
Per the FY2024 dividend-history disclosure and BMS's quarterly-dividend announcement press releases, the company has maintained and periodically raised the dividend across many decades.
Per the FY2024 balance sheet, interest-bearing debt of $51.5B against $10.3B cash is elevated — a residual from the Celgene acquisition financing plus the 2024 Karuna and RayzeBio transactions. The $13.9B FCF supports service capacity and disclosed deleveraging targets in investor-day materials.
Capital allocation scores 78/100. BMS is deploying cash the way a large pharma facing a patent transition usually must: defend the dividend, manage leverage, and use M&A to pull forward replacement revenue. That makes the capital-allocation file look more urgent than Gilead's. The issue is not capacity, because the cash flow is there; it is whether management is buying the right bridge assets at the right price.
Key Risks
Per the FY2024 Revlimid-revenue disclosure and the Celgene-era settlement agreement disclosed in prior 10-Ks, Revlimid (lenalidomide, for multiple myeloma) has entered a multi-year staggered generic-entry period that compresses product revenue through FY2025-26.
Per HHS CMS's public announcements under the Inflation Reduction Act, Eliquis is among the first 10 Medicare Part D drugs selected for negotiation with maximum fair prices effective January 1, 2026 per the CMS disclosure. The pricing impact is the principal long-term revenue-compression exposure.
Per the FY2024 Risk Factors, successful launch and label expansion of the growth-portfolio products (Camzyos, Cobenfy, Opdualag, Reblozyl) plus pipeline-asset-progression (including Karuna-origin KarXT now Cobenfy label expansions and RayzeBio radiopharmaceutical candidates) is the principal revenue-replacement pathway.
Per the FY2024 balance sheet, $51.5B of interest-bearing debt is elevated relative to pre-Celgene-acquisition levels. Service depends on sustained FCF generation; a prolonged new-product-uptake disappointment would compress deleveraging cadence.
Risk profile scores 62/100 (higher = safer). Per the FY2024 10-K, the principal watch-items are (1) the Revlimid LOE-driven staggered generic-entry revenue compression per the Celgene-era settlement, (2) Eliquis Medicare IRA drug-price-negotiation exposure (selected on the first list per HHS CMS disclosures, effective 2026), (3) new-product-launch execution on Camzyos/Cobenfy/Opdualag/Reblozyl as the revenue-replacement pathway, and (4) the $51.5B debt stack from Celgene + 2024 M&A financing whose deleveraging depends on FCF generation.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.